Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan/HDS in Unresectable HCC or ICC
NCT02415036Phase 2Terminated
- Sponsor
- Delcath Systems
- Start
- Jun 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Delcath Systems. Started Jun 2014; status: terminated.
02
Drugs
melphalan
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT02415036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415036.